Accelerate anti-fibrotic drug discovery with the 3D InSight™ Human Liver Fibrosis Model
At AASLD 2017, you'll have an opportunity to learn about a powerful new 3D cell-based model for for studying mechanisms of fibrosis induction and in vitro screening of anti-fibrotic drug efficacy.
- Rely on a physiologically relevant model commposed of primary human hepatocytes, hepatic stellate cells, kpffer cells, and liver endothelial cells
- Expand your assay window with a pre-qualified model that exhibits pro-fibrotic marker induction reflecting the in vivo disease state
- Perform reproducible, throughput-compatible anti-fibrotic drug screening using a standardized assay-ready model system
InSphero Liver Microtissue Product Manager Dr. Radina Kostadinova will be presenting compelling data generated using the 3D InSight™ Human Liver Fibrosis Model during the Basic Fibrosis Research and Stellate Cell Biology poster session on Friday, October 20. She and Field Application Scientist Judi Wardwell will be available throughout The Liver Meeting to discuss how you can leverage this advanced 3D model in your anti-fibrotic drug discovery research.
Your 3D InSight™ Conference Planner
October 20-24, 2017
Walter E. Washington Convention Center, Washington, DC USA
Friday, October 20, Presented 12:00 - 1:30 PM
Poster abstract #385: Development and characterization of a novel in vitro human liver fibrosis model for efficacy testing of anti-fibrotic drugs based on 3D Human Liver Microtissues
Poster Session I: Basic Fibrosis Research and Stellate Cell Biology | 8:00 AM - 5:30 PM